Agilent Technologies Inc. (A) Q3 FY2026 8-K Filings and Company Events

Filings that contain financial statements

Each earnings release below is furnished as Exhibit 99.1 to a Form 8-K (Item 2.02) and carries a condensed statement of operations, balance sheet and statement of cash flows, labelled preliminary and unaudited, plus non-GAAP reconciliations and segment tables.

• Form 8-K filed August 26, 2026, accession 0001090872-26-000062: fiscal third quarter ended July 31, 2026. Three- and nine-month statements of operations, balance sheet at July 31, 2026 against October 31, 2025, and nine-month cash flow statement.
• Form 8-K filed May 27, 2026, accession 0001090872-26-000052: fiscal second quarter ended April 30, 2026. Three- and six-month statements of operations, balance sheet, and six-month cash flow statement.
• Form 8-K filed February 25, 2026, accession 0001090872-26-000015: fiscal first quarter ended January 31, 2026. Statements of operations, balance sheet, and cash flow statement.
• Form 8-K filed November 24, 2025, accession 0001090872-25-000070: fourth quarter and full fiscal year ended October 31, 2025. Statements of operations, balance sheet, and full-year cash flow statement.
• Form 8-K filed August 27, 2025, accession 0001090872-25-000034: fiscal third quarter ended July 31, 2025. Three- and nine-month statements of operations, balance sheet, and nine-month cash flow statement.

Earnings and guidance

Guidance moved up at each of the last three reports. Fiscal 2026 revenue guidance went from a range of $7.3 billion–$7.4 billion (November 24, 2025, accession 0001090872-25-000070) to $7.3 billion–$7.5 billion (February 25, 2026, 0001090872-26-000015), $7.39 billion–$7.49 billion (May 27, 2026, 0001090872-26-000052) and $7.49 billion–$7.51 billion (August 26, 2026, 0001090872-26-000062). The non-GAAP EPS range went from $5.86–$6.00 to $5.90–$6.04, $6.00–$6.10 and $6.18–$6.21.

• August 26, 2026 (fiscal Q3 2026), accession 0001090872-26-000062. Revenue was $1.88 billion, up 8.1% reported and 7.3% core, against $1.74 billion a year earlier. GAAP net income was $362 million ($1.28 per share, up 8%); non-GAAP net income was $459 million ($1.62 per share, up 18%). Non-GAAP operating margin was 28.3%, up 320 basis points year over year, and included about 110 basis points of net benefit from tariff refunds ($20 million to operating income, $17 million to net income, $0.06 per share). Segment revenue: Life Sciences and Diagnostics Markets $746 million (up 11%), CrossLab $786 million (up 6%), Applied Markets $346 million (up 7%). Fiscal 2026 revenue is now expected at $7.49 billion to $7.51 billion (up 7.8% to 8.1% reported, 5.8% to 6.0% core), non-GAAP EPS $6.18 to $6.21 (up $0.15 at the midpoint, including the $0.06 tariff-refund benefit), and non-GAAP operating margin expansion of over 130 basis points. Fourth-quarter guidance is revenue of $1.98 billion to $2.0 billion and non-GAAP EPS of $1.71 to $1.74, with no further tariff-refund benefit assumed.
• May 27, 2026 (fiscal Q2 2026), accession 0001090872-26-000052. Revenue was $1.83 billion, up 10.0% reported and 6.3% core. GAAP net income was $339 million ($1.20 per share); non-GAAP EPS was $1.49, up 14%. Fiscal 2026 revenue guidance was raised to $7.39 billion to $7.49 billion and non-GAAP EPS to $6.00 to $6.10 (up $0.08 at the midpoint). Third-quarter guidance was revenue of $1.83 billion to $1.85 billion and non-GAAP EPS of $1.48 to $1.50.
• February 25, 2026 (fiscal Q1 2026), accession 0001090872-26-000015. Revenue was $1.80 billion, up 7.0% reported and 4.4% core. GAAP EPS was $1.07 (down 4%) and non-GAAP EPS $1.36 (up 4%). The company cited a major U.S. snowstorm in the last week of the quarter. Fiscal 2026 guidance was revenue of $7.3 billion to $7.5 billion and non-GAAP EPS of $5.90 to $6.04, with the EPS range modestly increased for favorable currency.
• November 24, 2025 (fiscal Q4 and full-year 2025), accession 0001090872-25-000070. Fourth-quarter revenue was $1.86 billion (up 9.4% reported, 7.2% core); GAAP EPS was $1.53 and non-GAAP EPS $1.59. Fiscal 2025 revenue was $6.95 billion (up 6.7%), GAAP net income $1.303 billion ($4.57 per share) and non-GAAP EPS $5.59. Initial fiscal 2026 guidance was revenue of $7.3 billion to $7.4 billion and non-GAAP EPS of $5.86 to $6.00.
• August 27, 2025 (fiscal Q3 2025), accession 0001090872-25-000034. Revenue was $1.74 billion (up 10.1% reported, 6.1% core); GAAP EPS was $1.18 and non-GAAP EPS $1.37. Full-year 2025 revenue guidance was revised to $6.91 billion to $6.93 billion and non-GAAP EPS to $5.56 to $5.59.

Acquisition and financing

• Biocare acquisition, closed June 24, 2026. Agilent's Form 10-Q for the quarter ended July 31, 2026 (accession 0001090872-26-000064) states that on June 24, 2026 the company acquired 100 percent of the outstanding capital stock of BC Midco I, Inc. ("Biocare") for net consideration of $950 million, and that Biocare became a wholly owned subsidiary and is included in the Life Sciences and Diagnostics Markets segment. The filing records $549 million of goodwill and $520 million of other intangible assets from the deal. The cash flow statement in the August 26, 2026 release shows $950 million of payments to acquire businesses and intangible assets in the nine months. No Form 8-K among the filings reviewed announces the signing or the closing; the deal is described in the quarterly report and its figures appear in the August earnings release.
• $600 million senior notes, June 25, 2026, accession 0001193125-26-282845 (Form 8-K, Items 1.01 and 2.03). Agilent closed the sale of $600 million of 4.900% Senior Notes due January 15, 2032 in a private placement, priced at 99.968% of principal, with interest payable semi-annually from January 15, 2027. The notes are senior unsecured, not guaranteed by subsidiaries, and redeemable at a make-whole price (Treasury rate plus 10 basis points) until December 15, 2031 and at par thereafter. A registration rights agreement requires the company to use commercially reasonable efforts to complete an exchange offer by June 25, 2027, with additional interest of 0.25% to 0.50% a year if it defaults. The cash flow statement in the August earnings release shows $600 million of long-term debt proceeds in the nine months.
• Capital return. The August 2026 release shows nine-month share repurchases of $295 million and dividends of $216 million. The 10-Q (accession 0001090872-26-000064) reports a quarterly dividend of $0.255 per share and about $1,654 million of remaining authorization under the 2024 repurchase program as of July 31, 2026. The 2023 program was completed in September 2025.
• Restructuring. The 10-Q reports a new fiscal 2026 restructuring plan (workforce reduction) begun in the third quarter, with about $15 million of cost recorded in the quarter and substantially complete activity expected by the first quarter of fiscal 2027.

Management and board changes

• September 8, 2026, accession 0001193125-26-384426 (Items 5.02, 7.01). Board chair Boon Hwee Koh retired from the board effective September 4, 2026 after 23 years on the board, with no disagreement cited. Dow R. Wilson was elected chair effective the same day. Glenn Boehnlein, Stryker's chief financial officer from 2016 to 2025, was appointed a Class III director and named to the Audit and Finance Committee and the Compensation Committee.
• May 27, 2026, accession 0001090872-26-000052 (Item 5.02). Tim Downs, previously of Baker Hughes, was appointed Vice President, Chief Accounting Officer and principal accounting officer, effective the first business day after the 10-Q for the quarter ended April 30, 2026. Rodney Gonsalves, the corporate controller who had announced his retirement on March 5, 2026 (Form 8-K, accession 0001193125-26-096487), stays on as Vice President, Finance through about January 2027.
• May 4, 2026, accession 0001193125-26-202636 (Items 5.02, 7.01). Michael Buckner was appointed Chief Legal Officer. Bret DiMarco resigned as Senior Vice President, Chief Legal Officer and Secretary and remains a Special Advisor through December 1, 2026, under a transition agreement dated March 31, 2026 (Form 8-K filed April 3, 2026, accession 0001193125-26-142101; an amendment, accession 0001193125-26-142673, corrected only the EDGAR item designation).
• October 27, 2025, accession 0001193125-25-251622 (Items 5.02, 7.01). Adam S. Elinoff, previously Vice President, Investor Relations and Treasurer at Amgen, was appointed Senior Vice President and Chief Financial Officer effective November 17, 2025, at a base salary of $700,000. Gonsalves had served as interim CFO since July 31, 2025.
• July 15, 2025, accession 0001193125-25-159100, and amendment August 8, 2025, accession 0001090872-25-000028. CFO Robert W. McMahon resigned effective July 31, 2025, and Gonsalves was appointed interim CFO. The amendment disclosed his interim compensation (a bi-weekly stipend of $8,654 and a $1,000,000 restricted stock unit grant).

Governance

• March 18, 2026 annual meeting, Form 8-K filed March 20, 2026, accession 0001193125-26-117614 (Items 5.03, 5.07). Stockholders approved a Fourth Amended and Restated Certificate of Incorporation that declassifies the board over three years (227,305,896 votes for, 416,270 against), and the board adopted matching Fourth Amended and Restated Bylaws effective on filing of the certificate on March 19, 2026. Four directors were elected to three-year terms, say-on-pay passed, and PricewaterhouseCoopers LLP was ratified as auditor for fiscal 2026.